Heat Biologics Inc expected to post a loss of 30 cents a share - Earnings Preview

Scorpius Holdings

07/08/2021 03:53

* Heat Biologics Inc  HTBX.OQ   HTBX.O  is expected to show a
rise in quarterly revenue when it reports results on August 6
(estimated). 
* The Morrisville, North Carolina-based company is expected to
report   a 1.2% increase in revenue to $600 thousand from $593
thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Heat Biologics Inc is
for a loss of 30 cents per share. For the same quarter last
year, the company reported a loss of 35 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Heat Biologics
Inc is $22​, about 69.7% above​ its last closing price
of $6.67. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.28       -0.29      -0.31     Missed  -7.8
 Dec. 31 2020  -0.33       -0.35      -0.02     Beat    94.3
 Sep. 30 2020  -0.24       -0.23      -0.42     Missed  -84.6​
 Jun. 30 2020  -0.68       -0.66      -0.35     Beat    47.4
 Mar.          -0.70​      -0.70      -0.77     Missed  -10​
 31​ 2020​                                              
 Dec. 31 2019  -0.97       -1.00      -0.70     Beat    30.2​
 Sep. 30 2019  -1.00       -1.01      -0.98     Beat    3.4
 Jun. 30 2019  -0.77       -0.77      -0.91     Missed  -18.2
 This summary was machine generated August 7 at 02:53 GMT.  All
figures in US dollars unless otherwise stated